Visceral leishmaniasis (VL) is a serious parasitic disease causing considerable mortality
and major disability in the Indian subcontinent. It is most neglected tropical disease …

Amphotericin B is a low-soluble polyene antibiotic which is able to self-aggregate. The
aggregation state can modify its activity and pharmacokinetical characteristics. In spite of its …

It is important to realize that leishmaniasis guidelines cannot always account for individual
variation among patients. They are not intended to supplant physician judgment with respect …

Leishmaniasis, usually caused by the genus Leishmania, has not received the attention it
deserves and in recent times has developed into a major health problem worldwide. 1, 2 …

Leishmaniasis remains a public health problem worldwide, affecting approximately 12
million people in 88 countries; 50 000 die of it each year. The disease is caused by …

Background Leishmaniasis is increasingly reported among travellers. Leishmania species
vary in sensitivity to available therapies. Fast and reliable molecular techniques have made …

Recent years have seen a significant improvement in available treatment options for
leishmaniasis. Two new drugs, miltefosine and paromomycin, have been registered for the …

Human visceral leishmaniasis (VL), a potentially fatal disease, is most prevalent in the
Indian subcontinent, East Africa and South America. Definite diagnosis and effective …

Introduction As of 2021, visceral leishmaniasis (VL) elimination program has met with
success in reducing the rate of VL to target levels in many locales, but there is persistence of …

Background: In leishmaniasis, some drugs prescribed for treatment have toxic effects and
there are reports about drug resistance in some countries. Due to this fact, using herbal …